Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Liabilities (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Total Liabilities for 8 consecutive years, with $129.4 million as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities fell 2.04% year-over-year to $129.4 million; the TTM value through Mar 2026 reached $129.4 million, down 2.04%, while the annual FY2025 figure was $163.1 million, 14.56% up from the prior year.
  • Total Liabilities hit $129.4 million in Q1 2026 for Kymera Therapeutics, down from $163.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $180.8 million in Q4 2023 and bottomed at $113.0 million in Q4 2022.
  • Average Total Liabilities over 5 years is $144.5 million, with a median of $142.4 million recorded in 2024.
  • Year-over-year, Total Liabilities fell 29.04% in 2022 and then surged 60.01% in 2023.
  • Kymera Therapeutics' Total Liabilities stood at $113.0 million in 2022, then soared by 60.01% to $180.8 million in 2023, then fell by 21.22% to $142.4 million in 2024, then grew by 14.56% to $163.1 million in 2025, then decreased by 20.7% to $129.4 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $129.4 million, $163.1 million, and $155.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.